98%
921
2 minutes
20
Objective: To assess the interrelationship between cortical lesions and cortical thinning and volume loss in people with multiple sclerosis within cortical networks, and how this relates to future cognition.
Methods: In this longitudinal study, 230 people with multiple sclerosis and 60 healthy controls underwent 3 Tesla MRI at baseline and neuropsychological assessment at baseline and 5-year follow-up. Cortical regions (N = 212) were divided into seven functional networks. Regions were defined as either lesional or normal-appearing cortex based on presence of a cortical lesion on artificial intelligence-generated double inversion-recovery scans. Cortical volume and thickness were determined within lesional or normal-appearing cortex.
Results: Prevalence of at least one cortical lesion was highest in the limbic (73%) followed by the default mode network (70.9%). Multiple sclerosis-related cortical thinning was more pronounced in lesional (mean Z-score = 0.70 ± 0.84) compared to normal-appearing cortex (-0.45 ± 0.60; P < 0.001) in all, except sensorimotor, networks. Cognitive dysfunction, particularly of verbal memory, visuospatial memory, and inhibition, at follow-up was best predicted by baseline network volume of normal-appearing cortex of the default mode network [B (95% CI) = 0.31 (0.18; 0.43), P < 0.001]. Mediation analysis showed that the effect of cortical lesions on future cognition was mediated by volume loss of the normal-appearing instead of lesional cortex, independent of white matter lesion volume.
Interpretation: Multiple sclerosis-related cortical thinning was worse in lesional compared to normal-appearing cortex, while volume loss of normal-appearing cortex was most predictive of subsequent cognitive decline, particularly in the default mode network. Mediation analyses indicate that cortical lesions impact cognitive decline plausibly by inducing atrophy, rather than through a direct effect.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752103 | PMC |
http://dx.doi.org/10.1002/acn3.52261 | DOI Listing |
J Neurol
September 2025
Multiple Sclerosis Center, Sheba Medical Center, Derech Sheba 2, Tel Hashomer, Israel.
Introduction: Psychological stress has been proposed as a trigger for disease activity in multiple sclerosis (MS), but findings have been inconsistent. While prior research has focused largely on chronic stressors, little is known about how people with MS (pwMS) cope with acute, large-scale stress events such as war.
Objective: Examine the effects of wartime stress following the October 7, 2023 attack on disease activity in pwMS, and to assess whether emotional factors are associated with relapse risk during this period.
Background: Growing evidence suggests a close association between circulating micronutrient levels and neuroimmune diseases. Nevertheless, the causal relationship between them remains unclear. Furthermore, due to confounding factors, many micronutrients implicated in these diseases remain unidentified.
View Article and Find Full Text PDFBioimpacts
August 2025
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Introduction: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). CD4 CD25 Tregs, which normally suppress immune responses, exhibit impaired function in MS. Treg-derived extracellular vesicles (EVs) carry immunoregulatory proteins and miRNAs that modulate T-cell activity.
View Article and Find Full Text PDFClin Infect Dis
September 2025
Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background: Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating disease caused by JC polyomavirus (JCV), affecting immunocompromised individuals. We describe PML demographic, clinical, radiological and laboratory characteristics and survival over time and according to underlying condition in a large retrospective patient cohort.
Methods: This is a retrospective cohort including Italian PML patients observed between 1987 and 2024, with known year of diagnosis and underlying disease.